Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00950365
Recruitment Status : Unknown
Verified July 2009 by Montefiore Medical Center.
Recruitment status was:  Recruiting
First Posted : July 31, 2009
Last Update Posted : July 31, 2009
Eli Lilly and Company
OSI Pharmaceuticals
Information provided by:
Montefiore Medical Center

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : May 2011
  Study Completion Date : No date given